# Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

> **NCT04220892** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Jose Carrillo**

## Conditions studied

- High Grade Glioma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04220892
- **Lead sponsor:** Jose Carrillo
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-08
- **Primary completion:** 2020-07-08
- **Final completion:** 2020-07-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220892, "Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04220892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*